Lymphocyte subpopulations in patients with multiple primary tumors

Cancer

Volumn 85, Issue 9, 1999, Pages 2073-2076

  Robinson, Eliezer ^a,c   Segal, Ruth ^a   Struminger, Lily ^a   Faraggi, David ^a   El'ad Yarum, Ruchama ^b   Mekori, Tamar ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Lymphocyte subpopulation; Lymphocyte subsets; Multiple primary tumors; Second primary tumor

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; PRIORITY JOURNAL; SECOND CANCER; SUPPRESSOR CELL;

EID: 0033135536     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990501)85:9<2073::AID-CNCR26>3.0.CO;2-J     Document Type: Article

References (14)

1. Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 1970;25:362-7.
2. Stein JA, Adler A, Ben Efraim SB, Maor M. Immunocompetence, immunosuppression and human breast cancer. Cancer 1976;38:1171-87.
3. Mekori T, Segal R, Bartel A, Cohen Y, Robinson E. Immune investigations and therapy in patients with advanced lung cancer. Cancer Immunol Immunother 1980;7:251-5.
4. Reinherz EL, Kung PC, Goldstjein G, Schlossman SF. Separation of functional subsets of human T cells by monoclonal antibody. Proc Natl Acad Sci U S A 1979;76:4061-5.
5. Robinson E, Segal R, Vesely Z, Mekori T. Lymphocyte sub-populations in peripheral blood and malignant effusions of cancer patients. Eur J Cancer Clin Oncol 1986;22:191-3.
6. Fisher LD, van Belle G. Biostatistics: a methodology for the health sciences. New York: John Wiley & Sons, Inc., 1993.
7. Tancini G, Barni S, Rescaldani R, Fiorelli G, Viviani S, Lissoni P. Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. Oncology 1990;47:381-4.
8. Nicolini A, Ferrari P, Spinelli R, Carpi A, Sagripanti A, Ambrogi F. Cell-mediated immunity in breast cancer patients. Biomed Pharmacother 1996;50:337-43.
9. Iaffaioli RV, Frasci G, Rinaldi L, Del Vecchio L, Tortoriello A, Facchini G, et al. Value of the CD25+ CD16+ cell determination in defining the prognosis of operable breast cancer patients. Eur J Gynaecol Oncol 1993;14:412-8.
10. Yacyshyn MB, Poppema S, Berg A, MacLean GD, Reddish MA, Meikle A, et al. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 1995;61:470-4.
11. Lukac J, Kusic Z, Kordic D, Koncar M, Bolanca A. Natural killer cell activity, phagocytosis and number of peripheral blood cells in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 1994;29:279-85.
12. Sevcikova L, Hunakova L, Chorvath B, Turzova M, Boljesikova E. T-lymphocyte subsets [CD4/CD8 ratio] in breast cancer patients. Neoplasma 1992;39:219-22.
13. Hernberg M, Muhonen T, Pyrhonen S. Can the CD4+/ CD8+ ratio predict the outcome of interferon-α therapy for renal cell carcinoma? Ann Oncol 1997;8:71-7.
14. Pillai R, Balaram P, Nair BS, Hareendram NK, Padmanabhan TK, Nair MK. Lymphocyte subset distribution after radiation therapy for cancer of the uterine cervix. Cancer 1991;67: 2071-8.